Medical Device Network on MSN
ResMed completes $340M Noctrix Health acquisition
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome.
Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: ...
ResMed Inc. (NYSE:RMD) is one of the most undervalued large cap stocks to buy according to analysts. On June 1, ResMed ...
Resmed (NYSE:RMD) announced today that it completed its previously announced $340 million acquisition of Noctrix Health.
Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).SAN DIEGO, June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results